Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC3 | Q13507 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22481577 | 1.00 | TRPC3 (0.48) | TRPC3BCHETP53MAPTLMNA | |
| SCHEMBL29668327 | 1.00 | TRPC3 (0.48) | TRPC3BCHETP53MAPTLMNA | |
| SCHEMBL29668159 | 1.00 | TRPC3 (0.48) | TRPC3BCHETP53MAPTLMNA | |
| SCHEMBL22550809 | 0.89 | LMNA (0.40) | TRPC3TP53MAPTLMNAPOLB | |
| SCHEMBL29668194 | 0.88 | LMNA (0.45) | TRPC3MAPTLMNAPOLB | |
| SCHEMBL22481384 | 0.88 | LMNA (0.45) | TRPC3MAPTLMNAPOLB | |
| SCHEMBL22481471 | 0.87 | TRPC3 (0.52) | TRPC3TP53MAPTLMNA | |
| SCHEMBL22481580 | 0.87 | NAMPT (0.38) | TRPC3TP53MAPTLMNA | |
| SCHEMBL22481530 | 0.87 | NAMPT (0.38) | TRPC3TP53MAPTLMNA | |
| SCHEMBL29668399 | 0.87 | NAMPT (0.38) | TRPC3TP53MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332459-B2 | Benzimidazole derivatives and their uses | TEIJIN PHARMA LIMITED (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
| CN-111417394-A | Benzimidazole derivatives and uses thereof | 安进公司 | 2020-07-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | TRPC6, TRPV6, TRPM6 | TRPC3 9/4885BCHE 3039/4885TP53 4010/4885 |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TRPC6, TRPV6, TRPM6 | TRPC3 9/4885BCHE 3039/4885TP53 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.